Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers
The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers
Non-small Cell Lung Cancers
RADIATION: stereotactic ablative radiotherapy (SABR)|DRUG: Pentoxifylline
primary endpoint is to estimate overall treatment-related toxicity, 36 months-end of trial
Estimate progression free survival, 12 months|Estimate tumor failure, 12 months|estimate overall survival, 12 months
The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers